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Abstract  
Background Systemic Sclerosis (SSc) is a chronic 
autoimmune disease which presents immunological, 
endothelial dysfunction, skin and organs fibrosis. The 
inflammatory process is an important pathophysiology of 
systemic sclerosis. Disease activity assessment using 
clinical parameters of modified rodnan skin score 
(mRSS) changes and inflammatory laboratory 
parameters of C-Reactive Protein (CRP), Erytrocyte 
Sedimentation Rate (ESR) and soluble CD40 ligand. 
The European Scleroderma Study Group (EscSG) 
activity index uses CRP. CRP is higher sensitivity and 
specificity than ESR (80% and 91.2%). The study aim 
isto evaluate the correlation between CRP and sCD40L 
with disease activity by mRSS.  
Methods This research was a cross-sectional study, 
and data of mRSS and sCD40L were obtained from the 
study, “ A Double Blind Randomized Controlled Trials of 
Ciplukan Herbs on Clinical Improvement of Skin 
Disorders, Inflammatory Process, Immunology and 
Fibrosis in Scleroderma Patients.” CRP examination 
was done by using the rest samples of the study, 
conducted in December 2017. Data analysis with Rank-
Spearman and Pearson Correlation. 
Result There were fifty-eight subjects with mean age 
38 ± 11 years old. Most of subjects were female 
(94.8%) and with a late disease duration > 2 years 
(74.1 %). Subjects consisted of 35 (60.3%) diffuse 
SSc and 23 (39.7 %) limited SSc. CRP was 
measured by turbidimetric immunoassay. Median 
and range score of CRP serum was 2.89 (0.16–
17.29) mg/L, while the median of sCD40L was 6457 
(1018–17976) pg/mL, and the median of mRSS was 
17 (4–36). There was no correlation between CRP 
and sCD40L with mRSS (r = -0.134, p = 0.167; and r 
= 0.023, p = 0.433). Conclusion There was no 
correlation between CRP and sCD40L serum with 
mRSS in systemic sclerosis patients.  
Keyword: Systemic Sclerosis, Skin 
Fibrosis, CRP, sCD40L, and mRSS  
 
 
Introduction 
Systemic Sclerosis (SSc) is an chronic progressive 
autoimmune condition involving connective tissue, 
with inflammation process having major role in 
 
 
pathophysiology and the etiology of this condition 
are yet to be known for sure.1-3 Pathogenesis triad 
marked by vasculopathy, autoantibody production 
and tissue fibrosis.2,4,5 Fibrosis is an interaction 
result between immune system mediator and 
inflammation that trigger fibroblast formation 
causing collagen and extracellular matrix deposit. 
Fibrosis are the highest cause for morbidity and 
mortality rate in SSc.5-8  
SSc incidences are rare, estimated count 150─300 
cases per one million population. One study at Hasan 
Sadikin General Hospital in year 2014 showed 
significant increase in patient visit with connective 
tissue disease from 51.2% to 63.5% of total patients 
visit a year before to after the era of National Health 
Coverage.9 Prognosis on SSc limited type is relatively 
good with 10 years survival rate more than 70%, while 
diffuse type has a lower 10 years survival at 
40─60%.10 SSc affects patient quality of life from all 
aspects include physical, psychological and economy. 
Yearly cost for each SSc patient in USA and Canada 
are estimated around 140─200 million, related with 
younger age, disease severity level, disease activity 
and bad health status.11-13 Polymorphism in the gene 
level, has a major role in individual vulnerability to 
SSc.14 In accordance to “treat to target” philosophy, it 
is important to know the exact method to measure 
disease activity in SSc.11-13  
Clinical parameter such as skin fibrosis degree, 
changes in organ involvement and laboratory 
parameter which describe inflammation activity, 
immune activity, fibrosis and vascular can be used to 
measure disease activity in SSc.15 Modified Rodnan 
Skin Score (mRSS) is a tool in assessing skin fibrosis 
degree which already proven in several clinical trial 
and well corelated with skin biopsy.6 mRSS have 
several limitation such as subjectivity aspect of the 
examiner and not sensitive enough to assess minimum 
changes although clinically significant, because 
changes will be seen after 3 to 6 months.12,13,16 This 
event cause necessity for serum biological marker to 
assist mRSS in assessing disease activity more 
sensitive, objective, quantitatively and faster, 
especially in fibrosis process as the key factor in SSc 
and well correlated with mRSS.17,18 
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Inflammation process is among one major role in the 
pathophysiology of SSc. Biological marker showing 
inflammation process are Erythrocyte Sedimentation Rate (ESR), 
C-Reactive Protein (CRP) and soluble CD40 ligand (sCD40L). 
ESR and CRP are already known as inflammation marker in 
autoimmune condition to monitor disease activity, CRP is more 
sensitive than ESR. The European Scleroderma Trials and 
Research Group (EUSTAR) revised and validate disease activity 
scoring (EScSG activity index). In the revised scoring, ESR is no 
longer use, replaced by CRP due to its higher sensitivity and 
specificity (sensitivity 80%, specificity 91.2%).19 Previous study 
also shown that inflammation activity in SSc represent by ESR 
gave insignificant result to mRSS.20  
C-reactive protein (CRP) is able to measure severity level 
and disease activity in SSc, as well as describing bad 
prognosis.15 In study done by Ohtsuka et. al. 21 showed 
increase hs-CRP on 35% SSc patients.21 Muangchan et. al5 
showed increase of CRP on 26% SSc patients and there was 
correlation between CRP and mRSS generally in the diffuse 
type, especially in patient with longer illness duration, 
although the correlation is moderate (r= 0.4–0.5).5,15  
Other biological marker which is already being research is 
CD40, a cytokine with role in immune system cascade of the SSc 
pathogenesis.17 The CD40-CD40L ligand in SSc will activate 
fibroblast to proliferate and to produce proinflammation cytokine 
that will start the fibrosis process. Komura et.al.16 report sCD40L 
increased in SSc mostly in limited type. sCD40L is expected to 
be the inflammation marker correlated with disease activity based 
on mRSS.16 Inflammations process will activate platelet in 
producing thrombin which will cause secretion of CD40L 
proinflammation cytokine. This process are the base that CD40L 
can be inflammation process biology marker.22 Previous research 
showed weak positive correlation between sCD40L and mRSS 
with r = 0.290 (p = 0.013).20 Other study showed no significant 
correlation between sCD40L level and mRSS score with r = 
0.066 (p = 0.346).23 Another study showed significant correlation 
between sCD40L and CRP in restenosis post percutaneous 
coronary intervention patients, related to pathophysiology of 
patient endothelium damage.24 CD40L expression can influence 
increasing of CRP level in associate with inflammation process. 
It means that sCD40L will increase in SSc patients.16  
Therefore correlation between inflammation marker CRP 
and sCD40L to mRSS to assess disease activity is still 
controversial and limited. Study about CRP and sCD40L as 
inflammation markers linked with gene polymorphism are not 
yet done in Indonesia, therefore further study is needed to 
prove CRP and sCD40L as inflammatory biomarker to 
monitoring disease activity apart from mRSS. 
 
Methods  
Subject 
Research subjects are all SSc patients fulfilled ACR/EULAR 
2013 criteria, CRP examination was done by using the rest 
samples of the study done by Dewi S.20 in ““Double Blind 
Clinical trials Extract Ciplukan Herbs on Clinical Improvement 
of Skin Disorders, Inflammatory Process, Immunology and 
Fibrosis in Scleroderma Patients”, from May 2015 to 
 
 
June 2017, which fulfilled inclusion and exclusion criteria. 
Inclusion criteria are adult, age 18 years old or above, already 
diagnosed SSc in out-patient Rheumatology clinic, already 
have mRSS and sCD40L data. Subjects with comorbid such 
as rheumatoid arthritis25, systemic lupus erythematosus26, 
acute bacterial infection and tuberculosis infection27, chronic 
liver disease 28,29, chronic renal disease30, acute coronary 
syndrome31, hypertension32, diabetes mellitus33, obesity34, 
malignancy35, in therapy of estrogen/progestin, or statin are 
excluded.  
Serum sample which fulfilled the criteria are recorded the 
mRSS score and sCD40L, then underwent CRP assessment at 
Clinical Pathology Hasan Sadikin Hospital Laboratory. 
Hypertension criteria based on Guidelines for the management of 
arterial hypertension by European Society of Hypertension (ESH) 
2013, which is ≥ 140/90 mmHg or in therapy of anti-hypertension 
medication.32 Diabetes mellitus criteria based on guidelines 
established by Indonesian Endocrinology Society on 2015 that is 
FBG ≥ 126 mg/dL or 2-hour PPG ≥ 200 mg/ dL, already 
diagnosed by competent physician or in therapy with anti-diabetic 
medication.33 Obesity criteria based on International Obesity Task 
Force, The Asia-Pacific Perspective which is Body Mass Index 
(BMI) ≥ 25 kg/m2. BMI are stated in kg/m2 unit.34 Acute bacterial 
infection were diagnosed based on history taking and physical 
examination in order to obtain information whether there was 
acute infection event within the last 2 weeks such as upper 
respiratory tract infection (pharyngitis, tonsilitis, rhinitis 
bacterialis, acute otitis media), lower respiratory tract infection 
(acute bronchitis, pneumonia), urinary tract infection (cystitis, 
uretritis, acute pyelonephritis), skin bacterial infection 
(erysipelas, cellulitis, pyoderma, subcutaneous abscess), 
gastrointestinal tract infection (acute dysentery, acute 
appendicitis, acute pancreatitis, acute peritonitis, liver pyogenic 
abscess), neuro system infection (meningitis bacterialis, brain 
abscess), tuberculosis infection or already diagnosed one of the 
infection by the competent physician.27 Rheumatoid arthritis is 
diagnose based on history taking, assessment in accordance with 
Indonesian Rheumatology Association (IRA) guidelines on 2014, 
or already diagnosed as rheumatoid arthritis by competent 
physician.25 Systemic Lupus Erythematosus diagnosed based on 
IRA Recommendation on year 2011.26 Chronic liver disease was 
diagnosed based on history taking, SGPT level assessment based 
on AASLD criteria year 2015 dan 2016, or already diagnosed.28,29 
Chronic Renal Failure was diagnosed based on history taking, 
physical examination and estimated glomerular filtration rate 
(eGFR) value in accordance of KDIGO 2012, or already 
diagnosed chronic renal failure by the competent physician.30 
Acute coronary syndrome (ACS) was diagnosed based on history 
taking, assessment in accordance with Indonesian Heart 
Association guidelines on year 2015, or already diagnosed ACS 
by the competent physician.31 Estrogen/progestin or statin 
medication are the usage in the last one month or less. 
 
CRP concentration 
CRP quantitative measurement from blood serum of research 
samples done until reaching determined amount. The 
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measurement completed in simultaneously using C-Reactive 
Protein Extended Range (RCRP) method by Particle 
Enhanced Turbidimetric Immunoassay (PETIA) technique, 
cut off normal value < 0.3 mg/dL. 5 
 
Statistical Analysis 
This research is a sub-study from a study done by Dewi S.20 as an 
analytic observational study with cross-sectional approach, 
gathers mRSS score and sCD40L as secondary data, and also 
assessment of all baseline serum samples as biological sample 
already storage on temperature -80oC at Prodia laboratory. Data 
analysis using SPSS ver.20. Normalization data using 
Kolmogorov Smirnov test. Characteristics data are presented in 
mean and standard deviation if normally distributed or in median 
and range if not normally distributed. Data analysis using two 
methods univariate and bivariate analysis. Bivariate analysis with 
Pearson for data distributed normally or Rank Spearman for data 
distributed not normal. 
 
Result 
From the total of 61 patients, there were 58 patients fulfilled the 
inclusion criteria. Medical record tracking is done to obtained 
data regarding early condition of the subjects, prior medication 
taken, or any comorbid disease that could make the patient 
excluded from the analysis. Next step is processing blood sample 
that already storage in less than a year in -80 0C for CRP 
quantitative assessment at clinical pathology Hasan Sadikin 
Hospital laboratory. The data collected are then analyzed and 
presented in the form of tables and graphic. 
 
 
Table 1. Study Basic Characteristic Data 
 
Characteristic 
  N=58 
  
Mean ± SD or 
(unit) n (%) 
Median (min-max)    
Age (year old)   38±11 
Gender    
Male 3 (5,2)  
Female 55 (94,8)  
Type systemic sclerosis    
Limited 23 (39,7)  
Diffuse 35 (60,3)  
Illness duration    
≤ 2 year 15 (25,9)  
> 2 year 43 (74,1)  
BMI (kg/m2)   20,29 ± 3,19 
Medication history    
Methotrexate 51 (87,9)  
Steroid 43 (74,1)  
Cyclophosphamide 1 (1,7)  
Calcium channel blocker 23 (39,7)  
Aspilet 26 (44,8)  
Ciplukan herb 51 (87,9)  
Duration receiving medication    
Methotrexate   24 (1–84) 
Steroid   22 (1–67) 
Cyclophosphamide   7 
Aspilet   24 (2–72) 
Original Article  
 
Characteristic 
 N=58 
 
Mean ± SD or 
(unit) n (%) 
Median (min-max)   
Laboratory result   
Haemoglobin (g/dL)  12,7 ± 1,1 
Leukosit (/UL)  8200 (3670–19400) 
SGPT (U/L)  12 (5–42) 
GDS(mg/dl)  88 (66–148) 
eLFG (mL/min/1,73m2)  110,9 (30,9–172,2) 
Kreatinin (mg/dL)  0,67 (0,28–1,92) 
ESR (mm/hour)  37±22 
mRSS score  17 (4–36) 
sCD40L level (pg/mL)  6.457 (1.018–17.976) 
CRP level (mg/dl)  0,289 (0,016–1,729) 
 
Note: n=frequency %=percentage, SD=Standard Deviation, N=total 
subjects, SGPT= Serum Glutamic Oxaloacetic Transaminase (SGPT), 
RBG=Random Blood Glucose, eGFR= estimated-Glomerulus Filtration 
Rate Glomerulus, ESR=Erytrocyte Sedimentation Rate, CRP= C-reactive 
protein 
 
Based on Kolmogorov-Smirnov test of normality result 
with Lilliefors Significance Correction obtained that sCD40L 
value and mRSS had normal distribution, while CRP value 
were not normally distributed (p = < 0,001).  
Most of research subject are female with ratio 27:1. Mean 
age when first disease onset is 38 ± 11 years old. Most of the 
subject were diffuse type 35 subjects (60.3%), and mostly 
already diagnosed over 2 years, 43 subjects (74.1%).  
Table 2 present subjects characteristic based on cutaneous 
classification namely SSc diffuse type and limited type. Both 
type has significant different in mRSS score, while sCD40L 
and CRP has no significant difference. 
 
 
Table 2. Different between Systemic Sclerosis 
Limited Type and Diffuse Type  
 
Variable 
Systemic Sclerosis Type  
   
Limited Diffuse 
p-value  n=23 n=35   
MRSS 12 (4 – 36) 23 (9 – 34) <0.001* 
(median (range))    
sCD40L 6240 ± 2221 6732 ± 3908 0.586 
(mean ± SD)    
CRP 0.220 (0.016 – 1.729) 0.360 (0.040 – 1.391) 0.164 
(median (range))    
 
Note: *significant p-value < 0.05 
 
Bivariate correlation test between CRP and mRSS 
presented in scatter diagram Fig.1, it can be see that the data 
spread randomly and did not have trend pattern so there was 
no linearity visible both in CRP and sCD40L, implicating each 
variable CRP, sCD40L and mRSS are independent. Rank 
Spearman correlation test showed no correlation between CRP 
concentration and mRSS (r = -0.139, p = 0.149), and Pearson 
test analysis showed no correlation between sCD40L and 
mRSS (r = 0.009, p = 0.475). 
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Figure 1. Scatter Diagram Correlation of CRP  
and sCD40L with mRSS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
Subjects age mean on first onset of SSc were 38 ± 11 years, 
this result were coherence with SSc onset, higher on the 4-5 
decade of life, other literature said higher on the 3-4 decades 
of life.25,26 Mean age different compared with Allanore et al.13 
Fifty subjects were 57 ± 11 years and Alba et al.73 on 1037 SSc 
patients in Spain, which most onset happen in age range 20–
50 years old, with mean 45 ± 15 years. Different age on both 
population can be happen due to different race and gene 
polymorphism so that SSc event are more likely happen in 
older population in Caucasian population compared with 
Asia.14 Study in Japan done by Komura et al.16 from 49 
subjects that is 51.4 ± 15.6 years old. Difference in age 
between the research with Komura et al.16 although both were 
Asian race, it might be influenced by the gene polymorphism. 
Other factors that influence gene polymorphism are familial 
and geography.14  
Most of the subjects were female (94.8%) with ratio 27: 1. 
These results were resembling with the epidemiology of SSc, SSc 
is more common in female.3,4 Similar result also found in a study 
in Asia done by Komura et.al16 that is 92%. Other results in Asian 
race were female with ratio 9 : 1 done by Mulla et al.36. The study 
result show more female ratio compared with in US that is 3–
5:1.1,37 Overall from allprevious studies, majority subjects were 
female, it were related with the specificity SSc antibody that 
noticeable in female such as anticardiolipin 
 
 
antibody (ACA) found positive in around 92–95% female, it 
was also happen with anti-topo I antibody around 83%.3  
Most of the study subjects 35 (60.3%) were diffuse type SSc, 
while 23 subjects (39.7%) were limited type SSc. Similar result 
found in Komura et al study.16 more patients were diffuse type (27 
patients), while limited type only in 22 patients. Diffuse skin 
involvement in majority patients (71–87%) have strong 
correlation with the existence of anti topo-I and anti-fibroblas 
antibodies. About 37–60% diffuse type patients tipe diffuse 
carried anti-topo I antibody, while limited type is less from 10 %. 
This antibody can influence to disease activity, skin severity level 
and respond to immunosuppressant medication such as 
corticosteroids.3 Several antibody test which are more specific for 
SSc namely anticentromere, could be found in 40–50% diffuse 
type patients and 5–10% limited type. While antitopoisomerase 
(Scl-70) could be found in 30–35% diffuse type patients and 10–
20% in limited type.4  
Study subjects with disease period > 2 years were 43 
subjects (74.1%), while subjects ≤ 2 years were 15 subjects 
(25.9%). Similar with Allanore et al.13 which had subjects with 
disease period > 2 years were 32 subjects (64%). Study result 
showed a shorter period done by Walker et al.38 in Canada with 
mean duration 14.8 years. Mulla et al.36 compared disease 
period Caucasian and Asia patients, results obtained that 
Caucasian have mean of period duration 8.9 years, while Asia 
have mean in 7.3 years. Based on organ involvement timeline, 
SSc stage are divided into 2 phase namely early (first 2 years) 
and late (> 2 years).3 Study result showed shorter period can 
be due to time of SSc diagnose establishment were far later 
from the first symptom.  
Medication given to the subjects are varied, mostly are 
methotrexate (87.9%), followed by steroid (74.1%), aspilet 
(44.8%), ciplukan (50%) and Calcium channel blocker 
(39,7%). While others underwent chemotherapy were only 
1.7%. Therapy given to the subjects are in line with the newest 
SSc management, whereas therapy is not a monotherapy but 
also a combination therapy to treat immune respond, vascular 
disease, and body tissue fibrosis.39 DMARDs used as choice 
of therapy are methotrexate, d-penicillamine, azathioprine, 
MMF and cyclophosphamide, with its rule as immune-
suppressant therapy in SSc.39  
Based on assessment to mRSS score, median of mRSS score 
was 17. While in study done by Muangchan et al.5 there was no 
significant different in CRP and mRSS in “early” or “late”, no 
changes in mRSS score can be followed regarding with or without 
changes of CRP. mRSS is a validated tool to access fibrosis 
degree, which can be utilized to monitor disease progression also 
skin fibrosis response to therapy received. mRSS monitoring 
based on disease course from longitudinal study showed that 
mRSS will change after 3─6 months of therapy.40 Result of this 
study showed significant differentiation in mRSS score, in SSc 
limited type subjects had median mRSS score 12, while median 
mRSS score in diffuse type subjects was 23 with p value < 0.001. 
In Muangchan et al.5 mRSS mean score in limited type is 5,94 ± 
5,07, and in diffuse type is 18,34 ± 10,29. According National 
Institute of Health (NIH), mRSS describes abnormality which are 
more subjective and semiquantitative to skin density. At 
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this moment mRSS are validated to use in clinical practices and 
therapy evaluation, also have well correlation with skin biopsy. 
Median sCD40L concentration in this study was 6.457 pg/mL 
with range from 1.018 to 17.976 pg/mL. This value show 
sCD40L on the study subjects was higher than control in study 
done by Allanore et al.13 which is median 79 (50–118) pg/mL and 
higher compared with the subject in Allanore et al.13 with median 
495 (10–2.690) pg/mL. Different results can be caused by this 
study used cross-sectional method, involved old patients whom 
already under treatment with immunosuppressants or still have 
high disease activity despite already receive therapy, while 
Allanore et al.13 used prospective method and exclusion done to 
subjects who received immunosuppressant and vasodilator 
medication.  
CRP examination method in this study is Particle Enhanced 
Turbidimetric Immunoassay (PETIA), results show median 0.289 
mg/dL (2.89 mg/L) with range 0.016 mg/dl (0.1 mg/L)–1.729 
mg/dl (17.29 mg/L), and cut off the normal value was < 0.3 mg/dl 
(< 3 mg/L). There were 29 subjects (50%) with elevated CRP 
concentration level, and there was no different either diffuse type 
nor limited type. CRP concentration were not significantly 
different in diffuse type nor limited type with median CRP 2.2 
mg/L in limited type and 3.6 mg/L in diffuse type (p = 0.164). 
Similar results obtained by Alekprov et al.41 that no different 
between diffuse and limited type. These event might be happen 
due to limited sample size, in the study only 59 samples not 
fulfilled the minimum sample size, so as Alekprov et al.41 with 
only 20 samples. Muangchan et al.5 obtained median CRP level 
is 3.60 mg/L, and there was significant different between diffuse 
and limited type, whereas increased CRP concentration mostly in 
diffuse type with duration of disease less than 2 years. . Different 
results of this studies might be happen due to different of total 
study samples and CRP examination method, while in 
Muangchan et al.5 study, total sample is bigger, confounding 
variable that could affect CRP concentration were excluded and 
also homogeneity are done such as medication history. Therefore, 
there was different method in CRP examination, in Muangchan 
et al.5 the cutoff point used are high if CRP > 8 mg/L, while in 
our study the cut off point used is > 3 mg/L.  
In this study, CRP increased in 50% patients, tit showed that 
CRP concentration in SSc patients can be permanent due to 
inflammation process, immunity, endothel damage and fibrosis 
cascade producing proinflammation cytokine and profibrotic, so 
that exacerbation, worsening of fibrosis reaction and remodeling 
process did not happen (vicious cycle).11,30 However, this result 
was not correlated with mRSS, this may be caused wide range of 
CRP concentration (0.1–17.29 mg/L). The wide range may be 
happened due to that the subjects were old patients with different 
type of therapy, medication dosage, and period receiving 
medication. The other factor which might be influence to CRP 
concentration is different refrozen process in each sample during 
study. Refrozen process can change CRP structure from pentamer 
to monomer, and refrozen on each sample are different so this 
effect the CRP concentration.51 Refrozen process (sample already 
expose to room temperature from the freezer, then refroze), and 
CRP level wide range, may also influence correlation results. 
Based 
Original Article 
 
on literature, refrozen process should be avoided because this 
process can change CRP structure and affect to the results. 
Sample storage in the study were in accordance with literature 
that the serum will be stable for more than 10 years if storage 
on below -700C.42  
Bivariate correlation analysis between CRP and mRSS 
showed that there was no correlation r = -0.139 dan p = 0.149. 
This result was different with previous study from Muangchan et 
al.5 on 1043 subjects that there was positive significant correlation 
between the high CRP concentration to disease activity in SSc, 
based on mRSS scoring (p < 0,01). Liu et al.43 study on 266 
patients showed significant correlation between CRP 
concentration with mRSS (p = 0.018) after excluded patients in 
immune-suppressants therapy. Ohtsuka et al.21 reported that hs-
CRP concentration increases in 35% SSc patients with unknown 
etiology, however it was estimated related to cytokine production 
include IL-6 and TNF-α. IL-6 concentrations showed 
intermediate correlation with hsCRP concentration (r = 0.69).21  
There is no correlation between CRP and mRSS might be 
caused by many confounding factors.5 In this study, all 
subjects receive immune-suppressant medication such as 
cyclophosphamide, methotrexate, and medication with anti-
inflammation effect namely steroid and ciplukan herb. Those 
medication can reduce mRSS score and CRP level. Mysler et 
al.44 study showed a dose of prednison 5 mg per day 
significantly reduce CRP level (p < 0.001). Systemic 
glucocorticoid reduce CRP concentration and IL-6.45 
Glucocorticoid suppress activity of interleukin, chemokine, 
cytokine, TNFα and macrophage.2,29  
Other factors which probably influence to different result 
compared to other study were total study subjects and different 
method used. Muangchan et al.5 study had 1043 subjects, 
while Liu et al.43 study had 266 subjects, both use prospective 
cohort approach and a multicenter study.  
Another condition which may cause no correlation 
between CRP level and mRSS score is tissue damage process 
is permanent. Disease activity in SSc can be assessed from 
CRP level changes when high disease activity in early stage 
and fluctuated during the disease course, so according to study 
done by Nagy et al.46 monitoring of CRP level will assist to 
evaluate the medication efficacy, however CRP level are 
easily influenced by several condition such as acute bacterial 
infection or immune-suppressant and anti-inflammation 
medication which mostly used by the subjects, although in 
SSc, CRP level can be constant as respond from fibrosis.21 
mRSS scoring done to evaluate tissue damage due to fibrosis 
and the assessment of skin fibrosis respond to new therapy can 
be done and evaluate at least after 3 months, this result 
correspond with clinical trial done by Khanna et al.47 that 
mRSS score does not have significant changes if assessed less 
than 3 months. Rapid changes of the disease activity are not 
aligned with tissue damage although medication was already 
givenit caused the difficulty to get the correlation between 
both.  
Correlation analysis result between sCD40L and mRSS 
showed that there was no correlation between sCD40L level 
and mRSS score (r = 0.009, p = 0.475). This result 
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match with study done by Allanore et al.13 whom stated that 
sCD40L concentration were not correlated with mRSS score 
and study done by Salim et al.23 showed that sCD40L 
concentration were not significantly correlated with mRSS (r 
= 0.066, p = 0.346). These result did not support theory that 
sCD40L express fibroblast activation and inflammation 
process in SSc.13 Although several study showed that this 
event is influenced by fibroblast inhibition by Th2 
lymphocyte involving CD40L which included in superfamily 
of Tumor Necrosis Factor, whereas more further investigation 
of this process are required.48  
This results? was different compared with result obtained 
by Fukasawa et al.49 whom reported that there was positive 
correlation between sCD40L level with mRSS, although there 
was no significant different between diffuse type nor limited 
type. sCD40L and mRSS correlation are more significant in 
shorter disease periods (< 2 years), Yan et al.24 additionally 
reported that there was significant correlation between 
sCD40L and CRP in patients restenosis post percutaneous 
coronary intervention, associated with endothel damage 
pathophysiology.24 CD40L expression can stimulate CRP 
surge related with inflammation process. sCD40L increased 
in SSc patients.16  
Different result compared to previous study were likely 
caused by different type of subjects which is most of the 
subject already had the disease over than 2 years, sCD40L 
increase mainly in early stage of disease as sort out in the 
study done by Fukasawa et.al.49 that CD40 plays important 
role in SSc early abnormalities, include overproduction of 
cytokine, tissue fibrosis and vascular damage. CD40L 
expression on T-cell that activated by peripheral lymphocyte 
are significantly higher in fibroblast on patients with early 
stage SSc and the interaction between both fibroblast and T-
cell have role in early stage fibrosis on the tissue.16,48  
Most of the subjects were old patient who already received 
therapy, this also influenceds CD40L level. Methotrexate is 
frequently used by subject in Hasan Sadikin Hospital, 
Methotrexate effects to body immune system were decreasing 
pro-inflammatory cytokine, extracellular adenosis release, 
inhibition on T-cell activation. T-cell activation inhibition in 
SSc may decrease CD40L expression therefore decrease 
sCD40L level in the serum.48 Methotrexate can also affect 
CD40L through inhibition of cell production and ligation 
proinflammation cytokines such as TNF, IL-6, IL-8, IL-1 
produced by monocyte, macrophage and lymphocyte.50 
Second, the most used therapy are steroid, steroid can induce 
lymphocyte apoptosis, mainly T-lymphocyte in the peripheral 
lymphoid organ and decrease T-lymphocyte migration to the 
inflamed tissue so that autoantibody production by the 
lymphocyte are decreased and this may influence CD40L 
score.51  
Fifty percent of the subjects received ciplukan herb 
therapy, ciplukan inhibit lymphocyte and monocyte on its 
function but did not affect the amount of it, especially T-
lymphocyte through inhibiting IL-2, Il-6 and IL-7 production 
by the lymphocyte. Ciplukan also inhibit macrophage 
activation in the inflamed tissue.52  
Bivariate analysis both CRP and sCD40L in this study 
 
did not reveal correlation of disease activity measure based on 
fibrosis level using mRSS. This could be happen due to the 
subjects in the study had SSc more than 2 years. CRP and sCD40L 
can increase mostly on early disease stage due to inflammation 
factor which was dominantly influenced by body immune, on the 
other hand, longer period of the disease, the tissue damage caused 
by fibrosis were more prominent. Increased level of CRP and 
sCD40L can be fluctuates in accordance with disease 
activity.3,5,16,48 The lack of correlation between CRP and sCD40L 
with mRSS can explain that decreasing of CRP will decrease 
inflammatory activity wich does not improve mRSS score in SSc. 
Inflammation process are less dominant compared with other 
process such as immune process or oxidative stress in influencing 
fibrosis cascade.15,30  
There were several limitations in the study which affect to 
the result such as1) Subjects were old patient, many 
confounding factors such as varied medication history, 2) 
Most of the subjects already received steroid therapy or any 
other immune suppressant affecting CRP level, 3) Most of 
research subject had already received DMARD methotrexate 
which can inhibit T-cell activation so that will affect to CRP 
and sCD40L level. 
 
Conclusion 
There is no correlation for CRP level to mRSS also between 
sCD40L level to mRSS in SSc patients. A study regarding CRP 
and sCD40L serum level related with disease activities based on 
mRSS score are better done in new patient whom not yet received 
any medication, and prospectively cohort monitored from starting 
the therapy until completion. CRP and sCD40L level 
measurement are not yet can be recommended as tool to help 
clinician in assessing disease activity based on skin fibrosis in SSc 
patients. CRP and sCD40L level interpretation should notice 
factors that might be affecting such as DMARD or steroid 
therapy, period of disease, also blood serum sample storage, if 
using storage biological samples. Fibrosis degree assessment 
using mRSS should be socialize through training and workshop 
to enhance physician skill to asses therapy response in SSc 
patients. 
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